Promising drug combo targets rare penile cancer in first major trial

NCT ID NCT07110038

Recruiting now Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 23 times

Summary

This study tests a combination of two drugs, enfortumab vedotin and avelumab, as a first treatment for men with advanced or metastatic penile cancer that cannot be cured by surgery. The goal is to see if the drugs shrink tumors and help patients live longer. About 25 men will take part in this early-stage trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Caritas St. Josef Medical Center
RECRUITING

Regensburg, Germany

Contact
Rostock University Medical Center
RECRUITING

Rostock, Germany

Contact
Technical University of Munich, University Hospital Munich
RECRUITING

Munich, Germany

Contact
University Hospital Mannheim
RECRUITING

Mannheim, Germany

Contact
University Hospital Tübingen
RECRUITING

Tübingen, Germany

Contact

Contact
University Medical Center of Johannes Gutenberg-University
RECRUITING

Mainz, Germany

Contact
Universitätsklinikum Carl Gustav Carus
RECRUITING

Dresden, Germany

Contact

Conditions

Explore the condition pages connected to this study.

PENILE SQUAMOUS CELL CARCINOMA (PSCC)